C
Christopher Halloran
Researcher at University of Liverpool
Publications - 108
Citations - 6189
Christopher Halloran is an academic researcher from University of Liverpool. The author has contributed to research in topics: Pancreatic cancer & Pancreatitis. The author has an hindex of 28, co-authored 93 publications receiving 4768 citations. Previous affiliations of Christopher Halloran include Royal Liverpool University Hospital & Royal Liverpool and Broadgreen University Hospital NHS Trust.
Papers
More filters
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial.
Markus K. Diener,Christoph M. Seiler,Inga Rossion,Jörg Kleeff,Matthias Glanemann,Giovanni Butturini,Ales Tomazic,Christiane J. Bruns,Olivier R. Busch,Stefan Farkas,Orlin Belyaev,John P. Neoptolemos,Christopher Halloran,Tobias Keck,Marco Niedergethmann,Klaus Gellert,Helmut Witzigmann,Otto Kollmar,Peter Langer,Ulrich Steger,Jens Neudecker,Frederik Berrevoet,Silke Ganzera,Markus M. Heiss,Steffen Luntz,Thomas Bruckner,Meinhard Kieser,Markus W. Büchler +27 more
TL;DR: Stapler closure did not reduce the rate of pancreatic fistula compared with hand-sewn closure for distal pancreatectomy and new strategies, including innovative surgical techniques, need to be identified to reduce this adverse outcome.
Journal Article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,Alec McDonald,Rodney William Carter,Niall C. Tebbutt,Christos Dervenis,D. Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Scarfe Ag,Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,M.W. Büchler +23 more
TL;DR: Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival Benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuant chemotherapy.
Journal ArticleDOI
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,A. C. McDonald,Ross Carter,Niall C. Tebbutt,Christos Dervenis,David Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Andrew Scarfe,Mark R. Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,Markus W. Büchler +23 more
TL;DR: In this article, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; 2 = 1.33; P=.25).
Journal ArticleDOI
Current standards of surgery for pancreatic cancer.
Nicholas Alexakis,Christopher Halloran,Michael Raraty,Paula Ghaneh,Robert Sutton,John P. Neoptolemos +5 more
TL;DR: Pancreatic cancer carries a dismal prognosis but there has been a vast increase in evidence on its management in the past decade.